Shobhit Seth

Shobhit Seth is a freelance financial writer, derivatives trader and consultant specializing in derivatives pricing and quantitative research. His career spans over 14 years as a Product Manager (Derivatives, Financial Data & Risk Management) at leading financial services companies across the UK, Europe, US and India. He has written extensively on topics pertaining to Derivatives Pricing, Derivatives Combinations & Structures, and Derivatives Trading Strategies. A lot of his work is available at, a site on Derivatives Trading which Shobhit owns and maintains. Shobhit also has expertise in index based products and ETFs, and he conducts training sessions on derivatives and related financial topics.

Shobhit has a Master’s degree in Financial Management (Specialization in Derivatives & Quantitative Research) from the Netherlands and a Bachelor of Technology degree (Electronics & Communications Engineering) from India.

  • Showing 1-15 of 606 items
  • 1
  • 2
  • 3
  • ...
  • 41
  • >>
  1. Stocks

    Amgen Invests in Israeli Digital Health Co. (AMGN)

    Amgen invested in an Israeli digital health incubator called eHealth Ventures.
  2. Stocks

    Biogen Posts 3Q Net of $1B on $3B Revenue (BIIB)

    Biogen reported 3Q earnings of $1 billion, or $4.97 per share, on revenue of $2.96 billion. Biogen's adjusted 3Q EPS of $5.19 beat analyst estimates.
  3. Stocks

    Vertex Posts 3Q Loss of $42 Million (VRTX)

    The results fell below the projected profit of 19 cents that analysts had estimated.
  4. Stocks

    Vertex Begins Two Cystic Fibrosis Studies (VRTX)

    Vertex Pharmaceuticals launched two Phase 2 studies to test a new class of cystic fibrosis drugs.
  5. Stocks

    Oasmia Buys Estrogen Receptor Cancer Drug (OASM)

    Oasmia Pharmaceutical, a Swedish drug company, agreed to purchase a cancer drug from fellow Swedish group Karo Pharma for $2.8 million in stock.
  6. Stocks

    Baxter Rolls Out New Kidney Filter Therapy (BAX)

    Baxter International launched a new dialysis therapy that more closely mimics the natural filtering capabilities of the kidney.
  7. Stocks

    Pluristem Stock Soars 8% on $30M Chinese VC (PSTI)

    Pluristem Therapeutics stock rose 8% after the Israeli biotech company received a $30 million investment from a Chinese venture capital firm.
  8. Stocks

    Medtronic's New Android App Monitors Glucose (MDT)

    Medtronic's glucose monitoring app, called MiniMed Connect, is now available on Android, the world’s most popular mobile operating system.
  9. Stocks

    Dipexium Foot Ulcer Study Fails Big Time (DPRX)

    Dipexium Pharmaceuticals stock got hammered after the company reported that its Locilex cream for diabetic foot ulcers failed in Phase 3 studies.
  10. Stocks

    Lexicon Diabetes Drug Shows Phase 2 Promise (LXRX)

    Lexicon Pharmaceuticals reported promising results from a Phase 2 trial of its type 1 diabetes drug, sotagliflozin.
  11. Stocks

    PTC Therapeutics $20M Milestone on Horizon (PTCT)

    PTC Therapeutics initiated a Phase 2 study for its RG7916 drug to treat Type 2 and Type 3 Spinal Muscular Atrophy (SMA) in children and adults.
  12. Stocks

    Aduro Cancer Study Put on Partial Hold (ADRO)

    Aduro stock fell by as much as 10% after the FDA put its Listeria-based cancer drug study on partial hold when 2 patients tested positive for Listeria.
  13. Stocks

    Inovio Falls as Cancer Study Put on FDA Hold (INO)

    Inovio stock fell 17% after the FDA put its cervical cancer drug study on hold, citing concerns about the shelf life of its Cellectra drug delivery device.
  14. Stocks

    Global Blood Sickle Cell Trial Moves Forward (GBT)

    Global Blood Therapeutics secured FDA approval to proceed with a Phase 3 trial for its GBT440 drug to treat sickle cell disease.
  15. Stocks

    Alkermes Depression Drug Shows Good Results (ALKS)

    Alkermes stock surged October 21 after it reported promising late-stage trial results for its antidepressant drug ALKS-5461.
  • Showing 1-15 of 606 items
  • 1
  • 2
  • 3
  • ...
  • 41
  • >>